IP-10 Expression in Patients with Chronic HBV Infection and Its Ability to Predict the Decrease in HBsAg Levels after...

Area of Science:

• Hepatology
• Immunology
• Virology

Background:

• Interferon-γ-inducible protein 10 (IP-10), or CXCL10, is linked to antiviral immunity and chronic hepatitis B (CHB) progression.
• The predictive value of baseline IP-10 for nucleoside/nucleotide analogue (NA) treatment efficacy in CHB remains unclear.

Purpose of the Study:

• To investigate the utility of baseline serum and intrahepatic IP-10 levels in predicting the efficacy of entecavir (ETV) therapy in CHB patients.
• To explore the association between IP-10 expression and liver inflammation, fibrosis, and hepatitis B virus (HBV) markers.

Main Methods:

• Systematic examination of intrahepatic and peripheral IP-10 levels before and after ETV treatment.
• Correlation analysis of baseline IP-10 with clinical parameters (ALT, AST, HBV DNA, HBsAg) and histological findings.
• In vitro experiments to assess IP-10's direct effect on hepatocyte apoptosis.

Main Results:

• Baseline IP-10 levels were elevated in CHB patients, correlating with increased liver inflammation and fibrosis.
• Higher baseline intrahepatic IP-10 predicted better prognoses and a greater decrease in HBsAg levels post-ETV therapy.
• Monocyte-derived IP-10 was higher in CHB patients compared to liver cirrhosis and healthy controls; IP-10 promoted hepatocyte apoptosis in vitro.

Conclusions:

• Baseline serological and histological IP-10 levels can predict CHB severity.
• IP-10 levels may serve as a biomarker for predicting the reduction of HBsAg during entecavir therapy.